CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5,000 enrolled
Drug / intervention
Clopidogreldrug
Likely dose
Clopidogrel 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02707445
NCT02707445N/ACompleted
CompareCT.gov

Prospective Multi-center Registry of Genotyping Related Clopidogrel in Percutaneous Coronary Intervention Patients

Korea University Anam Hospital·interventional·Posted Mar 14, 2016·Updated Mar 14, 2016

In Brief

A clinical study evaluating Clopidogrel for Myocardial Ischemia and CLOPIDOGREL, POOR METABOLISM of (Disorder). Completed, enrolled 5,000 participants.

Detailed Summary

This study evaluated epidemiology and clinical outcome of clopidogrel related various genotyping in Korean patients who had undergone percutaneous coronary intervention as a all comer registry form.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Ischemia, CLOPIDOGREL, POOR METABOLISM of (Disorder)
Countries--
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 14, 2016
Enrollment StartSep 1, 2011
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.3 years ago

Interventions

Clopidogreldrug

Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention